Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Treatment intensity and survival in patients with relapsed or refractory diffuse large B-cell lymphoma in Denmark: a real-life population-based study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Completeness of RET testing in patients with medullary thyroid carcinoma in Denmark 1997-2013: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The positive predictive value of spontaneous subarachnoid hemorrhage diagnoses in the Danish National Patient Register

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Incidence and prevalence of multiple endocrine neoplasia 2A in Denmark 1901-2014: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Correction: Educational delay and attainment in persons with neurofibromatosis 1 in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Publisher Correction: Mendelian randomisation study of the relationship between vitamin D and risk of glioma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Purpose: High-dose chemotherapy with autologous stem cell transplantation (ASCT) is considered to be the only curative treatment option for patients with refractory or relapsed diffuse large B-cell lymphoma (DLBCL). Due to toxicity, not all patients are eligible for this treatment leading to different treatment intensities. Here, we aim to analyze the impact of treatment intensity on survival in patients previously treated with rituximab and chemotherapy, and, furthermore, to analyze the association between socioeconomic position and treatment intensity, defined as palliation, non-salvage, and salvage regimens.

Materials and methods: We identified patients with refractory or relapsed DLBCL diagnosed in 2000-2015 in the Danish National Lymphoma Registry (n=1,228). We analyzed the impact of treatment intensity on survival in patients previously treated with rituximab (n=277) using a Cox proportional hazards model. Multinomial regression analyses were performed to identify associations between socioeconomic factors and treatment intensity for the entire cohort.

Results: In the rituximab era, the 5-year overall survival (OS) was 31% for patients receiving salvage regimens (n=194), and 17% for patients receiving non-salvage regimens (n=83). In the adjusted analysis, HR was 1.88, 95% CI: 0.9-3.9 for patients receiving salvage regimens. Patients living alone were significantly less likely to receive salvage regimens, as were patients with two or more comorbidities.

Conclusion: We observed a better OS in patients treated with salvage regimens compared with non-salvage regimens; however, the adjusted analysis contradicts this. Furthermore, our results indicate that there is a chance of remission for patients not eligible for ASCT.

OriginalsprogEngelsk
TidsskriftClinical Epidemiology
Vol/bind11
Sider (fra-til)207-216
Antal sider10
ISSN1179-1349
DOI
StatusUdgivet - 2019

ID: 57383209